Pharmacokinetics and biodistribution of Erufosine in nude mice - Implications for combination with radiotherapy

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Henke, Guido ^a   Lindner, Lars H ^b,c   Vogeser, Michael ^b   Eibl, Hans Jörg ^d   Wörner, Jürgen ^a   Müller, Arndt C ^a   Bamberg, Michael ^a   Wachholz, Kirsten ^b   Belka, Claus ^a,b   Jendrossek, Verena ^a,e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^e UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ERUFOSINE; LACTATE DEHYDROGENASE; MG 503 8; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ERUCYLPHOSPHO N,N,N TRIMETHYLPROPYLAMMONIUM; ERUCYLPHOSPHO-N,N,N-TRIMETHYLPROPYLAMMONIUM; ORGANOPHOSPHATE; QUATERNARY AMMONIUM DERIVATIVE; RADIOSENSITIZING AGENT;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BRAIN; COLON; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG TOLERABILITY; INJECTION SITE REACTION; KIDNEY; LIVER; LUNG; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUSCLE TISSUE; NONHUMAN; NUDE MOUSE; SMALL INTESTINE; SPLEEN; STOMACH; TANDEM MASS SPECTROMETRY; WEIGHT REDUCTION; ANIMAL; LIQUID CHROMATOGRAPHY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; COMBINED MODALITY THERAPY; MICE; MICE, NUDE; PHOSPHORIC ACID ESTERS; QUATERNARY AMMONIUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 71149120569     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-46     Document Type: Article

References (27)

1. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nature reviews 2008, 8(1):56-61. 10.1038/nrc2255, 18059462.
2. Hermann RM, Wolff HA, Jarry H, Thelen P, Gruendker C, Rave-Fraenk M, Schmidberger H, Christiansen H. In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol. Radiation oncology (London, England) 2008, 3:19. 10.1186/1748-717X-3-19, 2490684, 18625043.
3. Itani W, Geara F, Haykal J, Haddadin M, Gali-Muhtasib H. Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells. Radiation oncology (London, England) 2007, 2:1. 10.1186/1748-717X-2-1, 1770925, 17201910.
4. Candelaria M, Garcia-Arias A, Cetina L, Duenas-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiation oncology (London, England) 2006, 1:15. 10.1186/1748-717X-1-15, 1479830, 16722549.
5. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Seminars in radiation oncology 2003, 13(1):13-21. 10.1053/srao.2003.50002, 12520460.
6. Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Current medicinal chemistry 2003, 3(5):343-353.
7. Jendrossek V, Muller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 2003, 22(17):2621-2631. 10.1038/sj.onc.1206355, 12730676.
8. Mollinedo F. Antitumor ether lipids: proapoptotic agents wth multiple therapeutic indications. Expert Opin Ther Patents 2007, 17(4):385-405.
9. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer research 1999, 59(10):2457-2463.
10. Handrick R, Rubel A, Faltin H, Eibl H, Belka C, Jendrossek V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 2006, 80(2):199-206. 10.1016/j.radonc.2006.07.021, 16916558.
11. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti-cancer drugs 2003, 14(2):167-173. 10.1097/00001813-200302000-00011, 12569304.
12. Luit AH, Budde M, Zerp S, Caan W, Klarenbeek JB, Verheij M, Van Blitterswijk WJ. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. The Biochemical journal 2007, 401(2):541-549. 10.1042/BJ20061178, 1820802, 17049047.
13. Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer treatment reviews 2007, 33(2):191-202. 10.1016/j.ctrv.2006.12.001, 17287087.
14. Kotting J, Marschner NW, Neumuller W, Unger C, Eibl H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Progress in experimental tumor research Fortschritte der experimentellen Tumorforschung 1992, 34:131-142.
15. Verweij J, Planting A, Burg M, Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. Journal of cancer research and clinical oncology 1992, 118(8):606-608. 10.1007/BF01211805, 1325463.
16. Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002, 38(12):1615-1621. 10.1016/S0959-8049(02)00127-2, 12142051.
17. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004, 10(22):7450-7456. 10.1158/1078-0432.CCR-03-0406, 15569974.
18. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer chemotherapy and pharmacology 1999, 44(6):484-490. 10.1007/s002800051122, 10550569.
19. Rubel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiation oncology (London, England) 2006, 1:6. 10.1186/1748-717X-1-6, 1475859, 16722524.
20. Eibl H, Engel J. Synthesis of hexadecylphosphocholine (miltefosine). Progress in experimental tumor research Fortschritte der experimentellen Tumorforschung 1992, 34:1-5.
21. Lindner LH, Eibl H, Hossann M, Vogeser M. Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 869(1-2):16-19. 10.1016/j.jchromb.2008.05.007, 18508417.
22. Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Investigational new drugs 2005, 23(4):279-286. 10.1007/s10637-005-1436-0, 16012787.
23. Vink SR, Lagerwerf S, Mesman E, Schellens JH, Begg AC, van Blitterswijk WJ, Verheij M. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 2006, 12(5):1615-1622. 10.1158/1078-0432.CCR-05-2033, 16533789.
24. Planting AS, Stoter G, Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 1993, 29A:518-519. 10.1016/S0959-8049(05)80142-X, 8435202.
25. Stekar J, Hilgard P, Klenner T. Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer 1995, 31A(3):372-374. 10.1016/0959-8049(94)00495-Q, 7786605.
26. Jendrossek V, Kugler W, Erdlenbruch B, Eibl H, Lang F, Lakomek M. Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer research 2001, 21(5):3389-3396.
27. Kugler W, Erdlenbruch B, Otten K, Jendrossek V, Eibl H, Lakomek M. MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. International journal of oncology 2004, 25(6):1721-1727.